A capital-light thesis,
governed like it plans to scale.
Qazivo Biotech (OPC) Private Limited is structured to be transparent from its earliest days — because the credibility we're asking retailers, partners and regulators to extend us starts with the credibility of the company itself.
The entity, in brief
Qazivo Biotech is incorporated as a One Person Company (OPC) under the Companies Act, 2013 — a structure that gives a single-founder company full corporate personhood, limited liability, and a statutory nominee-director framework, while remaining lean enough to move quickly in its earliest phase.
Further statutory filings and financial disclosures will be added here as the company progresses through its early milestones.
Why nutraceuticals, why this structure
A structurally growing category
Consumer demand for preventive, evidence-informed health products is rising globally, and India's nutraceutical sector — backed by a deep botanical-sourcing base and a maturing regulatory regime — is positioned as both a production hub and a growth market in its own right.
Asset-light, standards-heavy
By directing formulation science and brand while contracting licensed, audited manufacturers for production, Qazivo avoids the fixed capital intensity of owning a plant — capital can instead be directed at R&D, quality assurance and market entry.
Global-standard from day one
Formulation dossiers, documentation and claims discipline are built to travel across regulatory regimes from the outset, reducing the cost and delay of later international expansion.
Discipline before it's required
As an OPC, Qazivo already operates with a statutory nominee-director structure and formal annual filing obligations under Indian company law. As the company raises capital and grows its team, we intend to convert to a private limited company with an independent board and formal audit and quality-oversight committees.
Financial statements, statutory filings and governance updates will be made available to prospective investors under appropriate confidentiality terms — reach out via the investor contact below to request our current data room.